Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561644 | 1.00 | THRB (0.32) | THRBALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL2687927 | 1.00 | THRB (0.32) | THRBALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL12883275 | 1.00 | THRB (0.32) | THRBALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL4742434 | 1.00 | THRB (0.32) | THRBALDH1A1MAPTHPGDMAPK1 | |
| SCHEMBL12247375 | 0.94 | THRB (0.32) | THRB | |
| SCHEMBL13804838 | 0.94 | THRB (0.32) | THRB | |
| SCHEMBL10041410 | 0.94 | THRB (0.32) | THRB | |
| SCHEMBL4170466 | 0.90 | TOP2A (0.32) | — | |
| SCHEMBL4170469 | 0.90 | TOP2A (0.32) | — | |
| SCHEMBL10039916 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-7915242-B2 | eczema, hypercalcemia, hyperparathyroidism, sarcoidosis, or vitamin D intoxication | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-7704981-B2 | 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2008089093-A2 | EFFICIENT PROCESSES FOR PREPARING STEROIDS AND VITAMIN D DERIVATIVES WITH THE UNNATURAL CONFIGURATION AT C20 (20 ALPHA-METHYL) FROM PREGNENOLONE | QUATRX PHARMACEUTICALS COMPANY (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | QUATRX PHARMACEUTICALS CO. | 2008-07-17 | — | — | US | disclosed |
| US-20070238705-A1 | 2-Methylene-1Alpha,25-Dihydroxy-18,19,21-Trinorvitamin D3 and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | CYP2R1, CYP24A1, VDR | THRB 818/4885ALDH1A1 1232/4885MAPT 4708/4885 |
| US-20070238705-A1 | 2-Methylene-1Alpha,25-Dihydroxy-18,19,21-Trinorvitamin D3 and Uses Thereof | CYP24A1, CYP27B1, CYP2R1 | THRB 362/4885ALDH1A1 701/4885MAPT 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.